High-throughput isolation of circulating tumor DNA: a comparison of automated platforms

Lisanne F. van Dessel1,2, Silvia R. Vitale1,2,3, Jean C. A. Helmijr1,2, Saskia M. Wilting1, Michelle van der Vlugt-Daane1,2, Esther Oomen-de Hoop1, Stefan Sleijfer1, John W. M. Martens1,2, Maurice P. H. M. Jansen1,2 and Martijn P. Lolkema1

1 Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands
2 Workgroup Cancer Genomics Netherlands, Erasmus MC Cancer Institute, University Medical Center Rotterdam, The Netherlands
3 Department of Clinical and Experimental Medicine, Center for Experimental Oncology and Hematology, University of Catania, Italy

Keywords
automation; cell-free DNA; circulating tumor DNA; isolation

Correspondence
M. P. Lolkema, Department of Medical Oncology, Erasmus MC Cancer Institute, Room NT-537, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
Tel: +31 10 704 19 06
E-mail: m.lolkema@erasmusmc.nl

Lisanne F. van Dessel and Silvia R. Vitale contributed equally to this article.

(Received 20 August 2018, revised 9 November 2018, accepted 19 November 2018, available online 22 December 2018)

doi:10.1002/1878-0261.12415

The emerging interest in circulating tumor DNA (ctDNA) analyses for clinical trials has necessitated the development of a high-throughput method for fast, reproducible, and efficient isolation of ctDNA. Currently, the majority of ctDNA studies use the manual QIAamp (QA) platform to isolate DNA from blood. The purpose of this study was to compare two competing automated DNA isolation platforms [Maxwell (MX) and QIAsymphony (QS)] to the current ‘gold standard’ QA to facilitate high-throughput processing of samples in prospective trials. We obtained blood samples from healthy blood donors and metastatic cancer patients for plasma isolation. Total cell-free DNA (cfDNA) quantity was assessed by TERT quantitative PCR. Recovery efficiency was investigated by quantitative PCR analysis of spiked-in synthetic plant DNA. In addition, a β-actin fragmentation assay was performed to determine the amount of contamination by genomic DNA from lysed leukocytes. ctDNA quality was assessed by digital PCR for somatic variant detection. cfDNA quantity and recovery efficiency were lowest using the MX platform, whereas QA and QS showed a comparable performance. All platforms preferentially isolated small (136 bp) DNA fragments over large (420 and 2000 bp) DNA fragments. Detection of the number variant and wild-type molecules was most comparable between QA and QS. However, there was no significant difference in variant allele frequency comparing QS and MX to QA. In summary, we show that the QS platform has comparable performance to QA, the ‘gold standard’, and outperformed the MX platform depending on the readout used. We conclude that the QS can replace the more laborious QA platform, especially when high-throughput cfDNA isolation is needed.

1. Introduction

With the discovery of cell-free DNA (cfDNA), first described in 1948 by Mandel and Metais (1948), and subsequently circulating tumor DNA (ctDNA; Stroun et al., 1989), a novel biomarker in cancer research became available. Since then, many studies have shown its great potential for detecting minimal residual disease and evaluating treatment response (Bidard et al., 2014; Dawson et al., 2013; Diaz and Bardelli, 2014; Diehl et al., 2008; Forshaw et al., 2012; Herbreteau et al., 2018; Murtaza et al., 2013; Pugh,

Abbreviations
cfDNA, cell-free DNA; cRNA, carrier RNA; ctDNA, circulating tumor DNA; dPCR, digital PCR; HBD, healthy blood donor; MX, Maxwell; QA, QIAamp; qPCR, quantitative PCR; QS, QIAsymphony; SNP, single nucleotide polymorphism; VAF, variant allele frequency.
2. Materials and methods

2.1. Subjects

Blood samples were obtained from a total of 10 HBDs and 10 metastatic cancer patients. HBDs were either laboratory volunteers or blood donors of the Sanquin Blood Bank South-West Region, The Netherlands. Patients were enrolled in this study between September 2016 and September 2017 within the Erasmus MC Cancer Institute in Rotterdam, the Netherlands. Eligibility criteria for patients have been described previously (van Dessel et al., 2017). All patients provided written informed consent, and the institutional review board approved the protocols (Erasmus MC ID MEC 15-616). The study methodologies conformed to the standards set by the Declaration of Helsinki. Patient and tumor characteristics are summarized in Table 1.

2.2. Blood collection

Healthy blood donors donated 20 mL of blood, collected either in 2 × 10 mL CellSave preservative tubes (Janssen Diagnostics, Raritan, NJ, USA) or in 1 × 10 mL EDTA tube (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and 1 × 10 mL CellSave preservative tube. Patients donated 3 × 10 mL of blood collected in CellSave preservative tubes. Blood samples were stored at room temperature until further processing. After blood draw, samples in EDTA tubes were processed within 24 h, whereas samples in CellSave tubes were processed within 96 h for plasma isolation as previously described (van Dessel et al., 2017).

2.3. cfDNA isolation

Cell-free DNA was isolated from 2 mL of plasma and eluted in 60 μL of the provided elution buffer. Three isolation platforms were evaluated (Table 2):

Table 1. Patient and tumor characteristics.

| Patient ID (#) | Primary tumor | Known somatic variant (nucleotide change) | Variant allele frequency in tissue (%) |
|---------------|---------------|------------------------------------------|----------------------------------------|
| BP-001        | NSCLC         | KRAS p.G12C (c.34G>T)                     | 32                                     |
| BP-003        | Melanoma      | NRAS p.G61R (c.182A>G)                    | 88                                     |
| BP-004        | Melanoma      | BRAF p.V600E (c.1799_1800delinsAA)        | 50                                     |
| BP-007        | Melanoma      | BRAF p.V600K (c.1798_1799delinsAA)        | 38                                     |
| BP-008        | CRC           | KRAS p.G12D (c.35G>A)                     | 45                                     |
| BP-009        | CRC           | PIK3CA p.E545K (c.1633G>A)                | 45                                     |
| BP-015        | CRC           | KRAS p.G13D (c.38G>A)                     | 40                                     |
| BP-016        | CRC           | KRAS p.G12V (c.35G>T)                     | Unknown                                |
| BP-023        | CRC           | KRAS p.G13D (c.38G>A)                     | Unknown                                |
| BP-028        | Melanoma      | BRAF p.V600K (c.1798_1799delinsAA)        | 55                                     |

CRC, colorectal cancer; NSCLC, non-small-cell lung cancer.
QIAamp (QA) Circulating Nucleic Acid Kit (Qiagen, Hilden, North Rhine-Westphalia, Germany); QIAsymphony (QS) SP Circulating DNA Kit (Qiagen); Maxwell (MX) RSC LV ccfDNA Plasma Custom Kit (Promega, Madison, WI, USA).

All cfDNA isolations were performed according to the manufacturer’s protocol, with some minor modifications. In more detail, cfDNA was isolated with QA as previously described (van Dessel et al., 2017). The QS isolation was adapted by adding 1 μL carrier RNA (cRNA, Qiagen) to the plasma sample preceding isolation. Using the MX platform, a third plasma centrifugation step at 2000 g for 10 min at room temperature was performed after thawing to eliminate residual leukocytes, as recommended by the manufacturer. The custom Maxwell® RSC ccfDNA Plasma Custom Kit for large plasma volume protocol was used. In brief, 2 mL of plasma was added to an equal amount of binding buffer and 140 μL of magnetic beads. This mixture was incubated under rotation for 45 min at room temperature and subsequently centrifuged at 2000 g for 1 min at room temperature. The pelleted mix of beads and cfDNA was then transferred to the cartridge and run on the MX instrument (Promega) according to the manufacturer’s protocol.

2.4. Testing of cRNA addition to the automated platforms

Plasma samples from several HBDs were pooled and divided into aliquots of 2 mL each. To each aliquot, we added different amounts of cRNA, ranging from 0.25 up to 4 μg. As a control, plasma samples without cRNA were included. To allow determination of the recovery efficiency, synthetic plant DNA was added to plasma samples (see below).

2.5. cfDNA quantification

All cfDNA samples were quantified by both Qubit™ fluorometric quantitation (Invitrogen, Life Technologies, Carlsbad, CA, USA) and human TaqMan® copy number reference assay TERT (Applied Biosystems, Life Technologies, Foster City, CA, USA) by quantitative PCR (qPCR). The Qubit™ measurement was performed on 2 μL of each cfDNA sample using the Quant-iT dsDNA high-sensitivity assay (Invitrogen), according to the manufacturer’s protocol. TERT qPCRs contained 5 μL cfDNA, 3.13 μL SensiFAST™ SYBR® Lo-Rox mix (Bioline, London, UK), and 0.62 μL TERT assay in a total reaction volume of 12.5 μL. The qPCR was performed on an Mx3000P Real-Time PCR System (Agilent, Santa Clara, CA, USA) with a pre-incubation at 95 °C for 10 min, followed by 45 cycles of 95 °C for 10 s and 60 °C for 22 s. cfDNA was quantified using a standard curve of human genomic DNA.

2.6. Synthetic plant DNA and plant DNA qPCR assay

The synthetic plant DNA assay developed by Kang et al. (2016) was used as an exogenous control to calculate the recovery efficiency of each cfDNA isolation method. In short, 250 ng of a 150-bp gBlocks® gene fragment (Integrated DNA Technologies Incorporation (IDT), Coralville, IA, USA) was resuspended in LoTe buffer to a final concentration of 1.64x10⁹ ng·μL⁻¹.
The stock sample was serially diluted to a final concentration of $1.64 \times 10^{-7}$ ng·µL$^{-1}$ of which 5 µL was spiked into plasma preceding cfDNA isolation. Plant DNA qPCRs were essentially performed as described above, using 900 nM of both forward and reverse primer and 250 nM of a FAM-labeled probe (Table S1). Recovery efficiency was determined using a standard curve including the amount of spiked-in plant DNA. Samples with a recovery efficiency < 5% or > 100% were excluded from further analysis as this strongly suggested an operator failure. This was further supported by the fact that recovery efficiency was not strongly correlated ($\rho = 0.45$) with cfDNA concentration (Fig. S1).

2.7. Digital PCR TaqMan® SNP genotyping and β-actin fragmentation assay

The presence of somatic tumor-specific variants and wild-type DNA molecules was determined using standard and custom-made TaqMan® single nucleotide polymorphism (SNP) genotyping assays (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions (Tables S2 and S3). The TaqMan® β-actin assay was used to investigate the fragment size distribution as an indication of leukocyte DNA contamination of the cfDNA, as previously reported (van Dessel et al., 2017). In short, a standard amount of 2 ng of cfDNA was used to detect one small (136 bp) and two long (420 and 2000 bp) β-actin fragments within a single reaction. The used primers and probes are indicated in Table S1. The digital PCR (dPCR) was performed as previously described (van Dessel et al., 2017). In short, a maximum volume input of 7.8 µL of the final cfDNA eluate was added to the dPCR; the dPCR run was performed on the chip-based QuantStudio 3D Digital PCR System (Thermo Fisher Scientific) according to the manufacturer’s protocol. SNP genotyping assays were run at 56 °C; the β-actin assay was run at 60 °C. A negative control (H2O) and a positive control (cell genomic DNA with known variant) were added to every experiment.

2.8. Sample size

To test whether QS and MX were comparable to QA, we assumed a Cohen’s effect size of 0.8, to be able to detect relevant differences. With a two-sided type I error probability (α) of 0.025 and a type II error probability (β) of 0.2, a power calculation determined that 18 subjects were needed for paired comparisons. Based on the foregoing, 20 subjects were included (10 HBDS and 10 patients).

2.9. Calculations and statistical analysis

All assay results were corrected for variations in plasma input and eluate volume, as previously described (van Dessel et al., 2017), and expressed as either ng·mL$^{-1}$ plasma or as mutant/wild-type/β-actin copy number per mL of plasma. The variant allele frequency (VAF) was calculated as follows: VAF = total variant copy number/(total variant copy number + total wild-type copy number).

The statistical analyses and figure plotting were performed in R version 3.2.3. The Friedman test was used to test the difference between matched QA, MX, and QS samples. Significant differences were post hoc analyzed using the Wilcoxon signed-rank test. To correct for multiple testing, we adjusted the $P$ value for significance by subsequently applying the Bonferroni correction. The Wilcoxon signed-rank test was used to test the difference between matched EDTA and CellSave samples. Correlations were determined by Spearman’s rank correlation coefficient.

3. Results

3.1. Optimization of cfDNA isolation using automated isolation platforms

In a small pilot study, we had previously observed a beneficial effect of cRNA addition to HBD plasma during isolation with the QS protocol on the cfDNA yield as determined by Qubit (Fig. S2). Therefore, cRNA addition was implemented in our standard QS protocol. However, it has been reported that cRNA might interfere with Qubit-based DNA quantification and might not be a reliable readout (Invitrogen, 2016). Therefore, we tested whether cfDNA isolation on the automated platforms (QS/MX) was beneficially or adversely affected by the addition of cRNA using multiple readouts. We added varying amounts of cRNA to the plasma samples and measured the resulting cfDNA concentration by Qubit and TERT qPCR for both automated platforms. Using Qubit as readout, the addition of cRNA increased the total amount of cfDNA extracted on both platforms (MX $P < 0.001$; QS $P < 0.001$; Fig. 1A). However, using TERT qPCR as readout, this increase could not be reproduced (Fig. 1B). Next, we assessed the impact of cRNA on the recovery of spiked-in synthetic plant DNA. Addition of cRNA affected the recovery efficiency of plant DNA (MX $P = 0.02$; QS $P = 0.04$; Fig. 1C). Independent of cRNA input, recovery of plant DNA was ~30% higher with QS (58.37 ± 9.52) than with MX (28.22 ± 6.67; $P < 0.001$). To assess whether the
addition of cRNA biased the isolation of particular cfDNA fragment sizes, we performed the β-actin fragmentation assay (Fig. 1D). For both methods, increasing amounts of cRNA reduced the number of small fragments (136 bp; MX \( P = 0.001 \); QS \( P < 0.001 \)), while no effect on larger fragments was observed. For all post hoc analyses, paired testing of samples with and without addition of cRNA (0 μg) did not reveal any significant differences.

3.2. Compatibility of CellSave preservative tubes with different isolation platforms

Previously, we have demonstrated the good performance of CellSave preservative tubes for ctDNA analysis (van Dessel et al., 2017). However, the manufacturers of both automated platforms recommend to use plasma isolated from blood collected in EDTA tubes. To allow for a fair comparison with our CellSave QA results, we therefore first determined whether the automated platforms (QS/MX) were compatible with CellSave tubes by assessing the cfDNA quantity and quality.

Figure 2A shows cfDNA concentrations as measured by TERT qPCR analysis. For the MX platform, the median cfDNA concentration was 5.59 ng·mL\(^{-1}\) plasma from EDTA tubes and was 2.19 ng·mL\(^{-1}\) plasma from CellSave tubes (IQR: 5.06–6.21 and 2.07–3.37 ng·mL\(^{-1}\) plasma, respectively; \( P = 0.008 \)). For the QS platform, the median cfDNA concentration was 17.17 ng·mL\(^{-1}\) plasma from EDTA tubes and 11.13 ng·mL\(^{-1}\) plasma from CellSave tubes (IQR: 7.81–22.12 and 9.02–14.14 ng·mL\(^{-1}\) plasma, respectively). Although this was comparable, EDTA samples displayed a larger range in yielded cfDNA concentration. The potential effect of CellSave tubes on the recovery

![Fig. 1. Effect of increasing cRNA input (0–4 μg) on cfDNA quantity and quality using the Maxwell and QIAsymphony platforms. The effect on cfDNA concentration (ng·mL\(^{-1}\) plasma) was measured by Qubit (A) and TERT qPCR (B). The recovery efficiency of each platform was analyzed by qPCR using spiked-in synthetic plant DNA (C). Differences in cfDNA fragment size, expressed as number of β-actin fragments for each fragment size (136, 420 and 2000 bp), were analyzed by dPCR (D). Boxes (interquartile ranges; IQR) and whiskers (1.5× IQR) are shown together with the median (black horizontal line). Outliers are indicated as single black points. Symbols ● and ▲ are mean values shown with whiskers (standard deviation). The Friedman test was used to test the group difference between Maxwell and QIAsymphony samples. Significant differences were post hoc analyzed using the Wilcoxon signed-rank test. \( N = 5 \).](image-url)
of synthetic plant DNA was determined as well. Comparable recovery efficiencies were observed in plasma collected in EDTA and CellSave tubes for both platforms (39.92% vs. 44.27% in MX and 67.92% vs. 66.19% in QS; Fig. 2B). Finally, we used the β-actin fragmentation assay to evaluate cfDNA fragmentation patterns as a readout for general sample quality (Fig. 2C). EDTA tubes yielded a higher number of large cfDNA fragments (2000 bp) irrespective of the platform used (median number of β-actin fragments and IQR MX: 33.08 (14.28–44.59); QS: 32.46 (25.53–55.44)) than CellSave tubes (median number of β-actin fragments and IQR MX: 5.15 (2.42–9.17); QS: 13.80 (7.01–18.18); \( P = 0.008 \)). The number of small DNA fragments (136 bp) did not differ between EDTA and CellSave tubes for MX, but was slightly higher for
EDTA tubes on the QS platform (median number of β-actin fragments and IQR EDTA: 142.71 (110.28–198.18); CellSave: 89.71 (80.22–102.64); P = 0.04). Based on these results, we deemed CellSave tubes are compatible with both automated platforms and used them for all further experiments.

3.3. Comparison of the performance of automated platforms on downstream cfDNA and ctDNA analyses

Next, we compared the quantity and quality of the obtained cfDNA using the current ‘gold standard’ manual QA platform to the automated QS and MX platforms using samples from 10 HBDs and 10 metastatic cancer patients. In HBDs, cfDNA concentrations measured by TERT qPCR analysis were comparable for all three isolation platforms (Fig. 3A). In patients, the MX retrieved significantly less cfDNA compared to both QA (P = 0.002) and QS (P = 0.002; median cfDNA concentration and IQR QA: 15.84 (12.64–65.11); MX: 6.00 (3.80–20.43); QS: 14.50 (11.99–57.65) ng mL⁻¹ plasma; Fig. 3A). To determine the recovery efficiency of the three different platforms, 5 μL of synthetic plant DNA was added to each plasma sample preceding cfDNA isolation. The average recovery efficiency using QA (51.95 ± 12.02%) was similar to QS (43.45 ± 8.21%). However, MX performed worse (18.61 ± 5.81%;

---

**Fig. 3.** Effect of the different isolation platforms (QIAamp, Maxwell, and QIAsymphony) on downstream cfDNA analysis. cfDNA was isolated from 2 mL matched plasma samples of HBDs (N = 10) and patients with metastatic cancer (N = 10) and analyzed by TERT qPCR assay for cfDNA concentration (ng mL⁻¹ plasma) (A), plant DNA qPCR assay to determine recovery efficiency (B), and dPCR β-actin fragmentation assay to evaluate cfDNA fragment sizes (C). Boxes (interquartile ranges; IQR) and whiskers (1.5× IQR) are shown together with the median (black horizontal line). Outliers are indicated as single black points. Symbols ■, ●, and ▲ are mean values shown with whiskers (standard deviation). The Friedman test was used to test the group difference between matched samples processed by the three platforms. Significant differences were post hoc analyzed using the Wilcoxon signed-rank test.
In HBDs, we did not observe cfDNA fragment size differences between either of the evaluated platforms (Fig. 3C). In patients, MX isolated fewer small β-actin fragments (136 bp) than QA (median number of β-actin fragments and IQR for MX: 57.45 (53.17–66.72); and for QA: 83.18 (70.36–101.63); P < 0.01) and fewer large fragments (2000 bp) than QS (median number of β-actin fragments and IQR for MX: 2.08 (0.00–5.21); and for QS: 10.06 (6.70–13.72); P = 0.002).

Finally, we compared somatic variant detection in ctDNA isolated by the different platforms. For this purpose, we used previously generated diagnostic sequencing results on the somatic variant status in the primary and/or metastatic lesions of the corresponding patients (Table 1). We detected the expected somatic variants in all patients for all isolation methods. QS results were most comparable to QA (Fig. 4). In MX, fewer mutant molecules, though not significant, and significantly fewer wild-type molecules were isolated (Fig. 4A,B). However, this did not result in a significantly different VAF (Fig. 4C).

### 4. Discussion

Up to now, several studies have investigated the effect of manual and automated cfDNA isolation platforms on ctDNA quantity and quality (Devonshire et al., 2014; Perez-Barrios et al., 2016; Sorber et al., 2017). However, differences in pre-analytical conditions, including plasma processing time, type of blood collection tube used, and storage conditions, hamper direct comparisons and straightforward conclusions. Here, we presented a study in which we have systematically optimized and compared automated isolation of cfDNA using QS and MX with the ‘gold standard’ QA.

The addition of carrier molecules like cRNA to plasma preceding cfDNA isolation increases the amount of cfDNA recovered during isolation by precipitating and binding of small molecules (Kishore et al., 2006; Shaw et al., 2009). The manual QA platform requires addition of cRNA for the standard protocol, whereas the manufacturer’s protocol of both the

---

**Fig. 4.** Somatic variant detection in patients with metastatic cancer on samples isolated with the three different isolation platforms (QIAamp, Maxwell, and QIAsymphony). Somatic variant status had been assessed in patients’ primary and/or metastatic lesion as part of the standard of care. In all patients (N = 10), the known somatic variant was detected in plasma isolated from the three platforms. The ratios of the mutant copy number (A), wild-type copy number (B), and variant allele frequency (VAF;C) measured in the Maxwell and QIAsymphony vs. QIAamp are shown. The dashed line (ratio of 1) resembles the situation when platforms have similar results. The Wilcoxon signed-rank test was used to test the difference between the platforms.
QS and MX does not require this. In a small pilot study, we observed that the addition of cRNA to the QS protocol improved cfDNA yield, so cRNA was implemented into our standard QS protocol. However, Invitrogen has reported that cRNA might interfere with Qubit-based DNA quantification. Indeed, our findings suggest that the increase in cfDNA concentration as measured by Qubit for QS and MX is, at least in part, affected by the presence of cRNA. Data obtained from the TERT and plant DNA qPCR did not reveal any added value of cRNA to either of the automated platforms. Moreover, our fragmentation assay suggests that increasing amounts of cRNA reduce the amount of small fragments. Together, our results demonstrate that addition of cRNA to plasma does not improve cfDNA yields using these automated bead-based platforms.

In our previous study using the manual QA platform, we demonstrated the superiority of CellSave tubes over EDTA tubes for collecting plasma for cfDNA/ctDNA analysis as it ensures optimal ctDNA quality when processed within 96 h after blood draw compared to only 24 h for EDTA tubes, enabling its use in multicenter clinical studies (van Dessel et al., 2017). Therefore, we investigated the compatibility of CellSave tubes with QS and MX. On both platforms, we observed an increase in the isolation of large cfDNA fragments (2000 bp) in EDTA samples. This relates to the release of intact DNA from lysed leukocytes and a subsequent increase in cfDNA concentration, which we also observed here. As the recovery efficiency was not affected in CellSave tubes and the plasma samples were not contaminated with additional DNA from leukocytes, we recommend the use of CellSave tubes in combination with the QS or MX platform.

Currently, QA is widely used for cfDNA/ctDNA isolations, but its manual laborious and time-consuming protocol renders this method unsuitable for high-throughput isolations. The competing automated platforms QS and MX both use magnetic-bead-based protocols and have comparable hands-on times. However, costs and number of samples that can be processed per run differ (Table 2). In HBDs, cfDNA quantity and quality were similar on all platforms. However, in patients we saw for all assays that QA and QS yielded more cfDNA than MX. As this might suggest that higher amounts of cfDNA are less efficiently isolated by the MX platform, we spiked high amounts of fragmented DNA in HBD plasma and isolated this with MX (Fig. S3). However, these high DNA amounts were isolated efficiently by MX. Another potential explanation for the difference in performance might be the absence of proteinase K incubation step in the MX protocol. Proteinase K is used in both the QA and QS protocols and can improve cfDNA yield by inhibiting nucleases and the release of protein-bound cfDNA. Moreover, recovery efficiency of plant DNA was lowest in MX. Altogether, this explains the lower yield of mutant and wild-type molecules isolated by MX, which may be a concern in samples with low frequent somatic variants. However, importantly, this lower yield did not translate into a significant difference in detected VAF (Figs 4C and S4). These data underline the importance of taking the used isolation method and readout (mutant molecules-mL⁻¹ plasma or VAF) into consideration when comparing results between studies as well as for the diagnostic use of ctDNA. QS and QA performed comparable in detection of absolute numbers of mutant and wild-type molecules. Of note, other publications have observed similar performances of QA and MX in a head-to-head comparison (Perez-Barrios et al., 2016; Sorber et al., 2017). This could be related to differences in pre-analytical conditions (e.g., type of blood collection tube, plasma volume used as input), as multiple publications have demonstrated its relation to cfDNA quantity and quality (Haselmann et al., 2018; van Dessel et al., 2017; Volckmar et al., 2018). In addition, we have optimized our QA protocol by re-eluting three times and thereby improving our cfDNA quantity. For automated magnetic-bead-based systems, this is not possible.

5. Conclusion

The results of this study show that the QS automated platform has comparable performance to the ‘gold standard’ QA and outperformed the MX platform depending on the readout used. The QS platform is congruent with all our predefined goals as it (a) reduces hands-on time from 180–240 to 30 min per run; (b) is able to process larger numbers of samples (96 instead of 24 at a time); (c) isolates comparable cfDNA yield with similar efficiency; and (d) has comparable ctDNA quantity and quality to QA. Therefore, the QS can replace the more laborious QA platform, especially when high-throughput cfDNA isolation is needed.

Acknowledgements

This work was supported in part by KWF-Alpe d’HuZes projects [EMCR 2014-6340 and NKI 2014-7080] and in part by a grant from Cancer Genomics Netherlands (CGC.nl)/Netherlands Organization for Scientific Research (NWO).
Conflict of interest
The authors declare no conflict of interest.

Author contributions
LFD and SRV acquired data, analyzed and interpreted data, and drafted and revised the manuscript; JCAH and MVD acquired data and revised the manuscript; SMW analyzed and interpreted data and revised the manuscript; EOH carried out statistical analyses and revised the manuscript; SS, JWMM, and MPL conceived the project and revised the manuscript; MPHMJ revised the manuscript; and all authors read, critically revised, and approved the final manuscript.

References
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM et al. (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6, 224ra24.

Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux N, Desjardins L, Milder M, Vaucher I et al. (2014) Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 134, 1207–1213.

Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B et al. (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368, 1199–1209.

Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA and Huggett JF (2014) Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406, 6499–6512.

Diaz LA Jr and Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32, 579–586.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985–990.

Elshimi YI, Khaddour H, Sarkissyan M, Wu Y and Vadgama JV (2013) The clinical utilization of circulating cell-free DNA (ccfDNA) in blood of cancer patients. Int J Mol Sci 14, 18925–18958.

Fleischhacker M and Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta 1775, 181–232.

Forshey T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D et al. (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4, 136ra168.

Haselmann V, Ahmad-Nejad P, Geilenkeuser WJ, Duda A, Gabor M, Eichner R, Patton S and Neumaier M (2018) Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). Clin Chem Lab Med 56, 220–228.

Herbreteau G, Vallee A, Knol AC, Theoleyre S, Quereux G, Varey E, Khammari A, Dreno B and Denis MG (2018) Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget 9, 25265–25276.

Invitrogen (2016) Qubit dsDNA assay specificity in the presence of single-stranded DNA. Application note.

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD and Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61, 1659–1665.

Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajyer SD, Rae JM and Tewari M (2016) Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and Cell Save blood collection tubes. Clin Biochem 49, 1354–1360.

Kishore R, Reef Hardy W, Anderson VJ, Sanchez NA and Buoncristiani MR (2006) Optimization of DNA extraction from low-yield and degraded samples using the BioRobot EZ1 and BioRobot M48. J Forensic Sci 51, 1055–1061.

Mandel P and Metais P (1948) Les acides nucleiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 142, 241–243.

Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshey T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS et al. (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112.

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM et al. (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20, 1698–1705.

Perez-Barrios C, Nieto-Alcalado I, Torrente M, Jimenez-Sanchez C, Calvo V, Gutierrez-Sanz L, Palka M, Donoso-Navarro E, Provencio M and Romero A (2016) Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res 5, 665–672.
Pugh TJ (2018) Circulating tumour DNA for detecting minimal residual disease in multiple myeloma. *Semin Hematol* **55**, 38–40.

Sefrioui D, Sarafan-Vasseur N, Beaussire L, Baretti M, Gangloff A, Blanchard F, Clatot F, Sabourin JC, Seseoue R, Frebourg T et al. (2015) Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. *Dig Liver Dis* **47**, 884–890.

Shaw KJ, Thain L, Docker PT, Dyer CE, Greenman J, Greenway GM and Haswell SJ (2009) The use of carrier RNA to enhance DNA extraction from microfluidic-based silica monoliths. *Anal Chim Acta* **652**, 231–233.

Shinozaki M, O’Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang HJ and Hoon DS (2015) Clinical value of circulating B-RAF DNA mutation in serum for detecting minimal residual disease in multiple myeloma. *Hematol J* **16**, 2068–2074.

Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C and Pauwels P (2017) A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. *J Mol Diagn* **19**, 162–168.

Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C and Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. *Oncology* **46**, 318–322.

van Dessel LF, Beije N, HelmiJR JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW et al. (2017) Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. *Mol Oncol* **11**, 295–304.

Volckmar AL, Sulmann H, Riediger A, Fioretos T, Schirmacher P, Endris V, Stenzinger A and Dietz S (2018) A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. *Genes Chromosom Cancer* **57**, 123–139.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Yu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK et al. (2015) Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. *Cancer Discov* **5**, 1040–1048.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Overview of the recovery efficiency of synthetic plant DNA in all samples isolated with the different platforms (QA, MX, and QS). (A) Dot plot of the recovery efficiency for each isolation platform, as analyzed by plant qPCR using spiked-in synthetic plant DNA. Samples with a recovery efficiency < 5% or > 100% (black horizontal lines) were excluded from the analyses. (B) Correlation between recovery efficiency and cfDNA concentration (ng mL⁻¹ plasma) measured by TERT qPCR assay. Correlations were tested by Spearman’s rank correlation coefficient. *P < 0.001.

**Fig. S2.** Effect of cRNA addition on cfDNA quantity using the QS platform. cfDNA concentration (ng mL⁻¹ plasma) was determined by Qubit after adding increasing amounts of cRNA (0–4 μg) before start of the plasma isolation. Boxes (interquartile ranges; IQR) and whiskers (1.5 × IQR) are shown together with the median (black horizontal line).

**Fig. S3.** Performance of the MX platform using increasing DNA input (0, 15, and 60 ng mL⁻¹ fragmented cell line DNA has been spiked in HBD plasma). The effects on (A) cfDNA concentration (ng mL⁻¹ plasma) measured by TERT qPCR, (B) recovery efficiency measured by plant DNA qPCR, (C) total number of mutant molecules, and (D) VAF are shown. Boxes (interquartile ranges; IQR) and whiskers (1.5 × IQR) are shown together with the median (black horizontal line). Outliers are indicated as single black points. Symbol ● is mean value shown with whiskers (standard deviation). N = 5.

**Fig. S4.** Representative data images of SNP genotyping dPCR assay isolated with the different platforms (QA, MX, and QS). A subject with an intermediate (A), high (B) and low (C) VAF are shown. On the X-axis, positive FAM signal represents mutant molecules (blue dots); on the Y-axis, positive VIC signal represents wild-type molecules (red dots). Green dots reflect the presence of a mutant and a wild-type molecule in a single well.

**Table S1.** Custom primer and probe sequences used for qPCR.

**Table S2.** Standard SNP genotyping assays.

**Table S3.** Custom SNP genotyping assays.